Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Better Buy: Biogen vs. Gilead Sciences

TheMotleyFool

0 0

Better Buy: Biogen vs. Gilead SciencesPhoto, wide shot, wide-angle lens, Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png

Despite a strong year for biotechnology stocks, Biogen (NASDAQ: BIIB) and Gilead Sciences (NASDAQ: GILD) both underwhelmed investors in 2019. Biogen's shares ended the year down 1.4%, whereas Gilead's stock eked out a modest gain of 3.88%. By contrast, the biotech funds iShares Nasdaq Biotechnology ETF and SPDR S&P Biotech ETF rose a healthy 25% and 32.5%, respectively, last year.

Which of these biotech giants has the better chance of breaking out of this funk in 2020? Let's take a look at how Biogen and Gilead compare on several key areas to find out.

Image source: Getty Images.

Source Fool.com

Like: 0

GILD

Teilen